Skip to Main Content
 

Global Search Box

 
 
 

ETD Abstract Container

Abstract Header

The effect of calcifediol supplementation on renin-angiotensin-aldosterone system mediators in dogs with chronic kidney disease

Miller, Matthew Scott
http://orcid.org/0000-0001-6543-1918
http://rave.ohiolink.edu/etdc/view?acc_num=osu1618829782648424

Abstract Details

2021, Master of Science, Ohio State University, Comparative and Veterinary Medicine.
Increased renin-angiotensin-aldosterone system (RAAS) metabolite concentrations instigate pro-fibrotic and pro-inflammatory changes within the kidney, potentially leading to worsening chronic kidney disease (CKD). Vitamin D metabolites have demonstrated the ability to serve as a negative endogenous regulator of the RAAS in humans. CKD, however, leads to decreased serum concentrations of vitamin D metabolites. We hypothesize that supplementation with calcifediol (25-hydroxyvitamin D) will decrease circulating RAAS mediators in dogs with CKD. Six dogs with IRIS Stage 2 and 3 CKD were retrospectively evaluated from a prior study involving the supplementation of calcifediol (25-hydroxyvitamin D). Dogs were supplemented with calcifediol for 3 months, after which calcifediol supplementation was discontinued. Dogs were evaluated at baseline (day 0), month 3, and month 5 (2 months after discontinuation of calcifediol). Vitamin D metabolites (25-hydroxyvitamin D, 1,25 hydroxyvitamin D, 24,25 hydroxyvitamin D) and RAAS mediators (angiotensin I/II/III/IV/1-5/1-7, and aldosterone) were evaluated at all time-points. Calculated surrogate values for plasma renin activity (PRA) and angiotensin-converting enzyme (ACE) activity were also evaluated. RAAS mediators were determined using a novel liquid-chromatography-tandem mass spectroscopy assay (RAS FingerprintTM). There was no significant difference in the concentration of any RAAS parameters between any time-point. The surrogate for ACE activity was significantly lower at month 3 compared to baseline (p = 0.01). No other RAAS mediators were affected by medications at any time-point. In conclusion, short-term calcifediol supplementation in this small subset of CKD significantly impacted ACE activity.
Valerie Parker (Advisor)
Jessica Quimby (Committee Member)
Catherine Langston (Committee Member)
38 p.
Endocrinology; Medicine
calcifediol; CKD; RAAS; renin; angiotensin

Recommended Citations

Citations

  • Miller, M. S. (2021). The effect of calcifediol supplementation on renin-angiotensin-aldosterone system mediators in dogs with chronic kidney disease [Master's thesis, Ohio State University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=osu1618829782648424

    APA Style (7th edition)

  • Miller, Matthew. The effect of calcifediol supplementation on renin-angiotensin-aldosterone system mediators in dogs with chronic kidney disease. 2021. Ohio State University, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=osu1618829782648424.

    MLA Style (8th edition)

  • Miller, Matthew. "The effect of calcifediol supplementation on renin-angiotensin-aldosterone system mediators in dogs with chronic kidney disease." Master's thesis, Ohio State University, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=osu1618829782648424

    Chicago Manual of Style (17th edition)

osu1618829782648424
196
© 2021, all rights reserved.
This open access ETD is published by The Ohio State University and OhioLINK.